Search Results - "FOGELMAN, David"

Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer by Pairawan, Seyed, Hess, Kenneth R, Janku, Filip, Sanchez, Nora S, Mills Shaw, Kenna R, Eng, Cathy, Damodaran, Senthilkumar, Javle, Milind, Kaseb, Ahmed O, Hong, David S, Subbiah, Vivek, Fu, Siqing, Fogelman, David R, Raymond, Victoria M, Lanman, Richard B, Meric-Bernstam, Funda

“…Physicians are expected to assess prognosis both for patient counseling and for determining suitability for clinical trials. Increasingly, cell-free…”
Get full text

Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer by Mehrvarz Sarshekeh, Amir, Advani, Shailesh, Overman, Michael J, Manyam, Ganiraju, Kee, Bryan K, Fogelman, David R, Dasari, Arvind, Raghav, Kanwal, Vilar, Eduardo, Manuel, Shanequa, Shureiqi, Imad, Wolff, Robert A, Patel, Keyur P, Luthra, Raja, Shaw, Kenna, Eng, Cathy, Maru, Dipen M, Routbort, Mark J, Meric-Bernstam, Funda, Kopetz, Scott

“…SMAD4 is an essential mediator in the transforming growth factor-β pathway. Sporadic mutations of SMAD4 are present in 2.1-20.0% of colorectal cancers (CRCs)…”
Get full text

Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study by Phan, Alexandria T, MD, Halperin, Daniel M, MD, Chan, Jennifer A, MD, Fogelman, David R, MD, Hess, Kenneth R, Prof, Malinowski, Paige, BA, Regan, Eileen, MSN, Ng, Chaan S, Prof, Yao, James C, Prof, Kulke, Matthew H, MD

“…Summary Background Treatment options for advanced, well-differentiated neuroendocrine tumours (NETs) remain scarce. Pazopanib is an orally bioavailable, small…”
Get full text

Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer by Perri, Giampaolo, Prakash, Laura, Wang, Huamin, Bhosale, Priya, Varadhachary, Gauri R., Wolff, Robert, Fogelman, David, Overman, Michael, Pant, Shubham, Javle, Milind, Koay, Eugene, Herman, Joseph, Kim, Michael, Ikoma, Naruhiko, Tzeng, Ching-Wei, Lee, Jeffrey E., Katz, Matthew H. G.

“…OBJECTIVE:We sought to identify potential radiologic and serologic markers of pancreatic tumor response to therapy, using pathologic major response (pMR) as…”
Get full text

Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer by Parseghian, Christine M, Parikh, Nila U, Wu, Ji Yuan, Jiang, Zhi-Qin, Henderson, Laura, Tian, Feng, Pastor, Brice, Ychou, Marc, Raghav, Kanwal, Dasari, Arvind, Fogelman, David R, Katsiampoura, Anastasia D, Menter, David G, Wolff, Robert A, Eng, Cathy, Overman, Michael J, Thierry, Alain R, Gallick, Gary E, Kopetz, Scott

“…Aberrant activation of the intracellular tyrosine kinase Src has been implicated as a mechanism of acquired chemotherapy resistance in metastatic colorectal…”
Get full text

Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma by Korphaisarn, Krittiya, Morris, Van, Davis, Jenifer S., Overman, Michael J., Fogelman, David R., Kee, Bryan K., Dasari, Arvind, Raghav, Kanwal P. S., Shureiqi, Imad, Trupti, Metha, Wolff, Robert A., Eng, Cathy, Menter, David G., Hamilton, Stanley, Kopetz, Scott

“…Background Signet ring cell carcinoma (SRCC) is a rare subtype of colorectal cancer (CRC). The aim of this study was to characterise the genomic alterations…”
Get full text

Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer by Goldstein, Jennifer B, Zhao, Li, Wang, Xuemei, Ghelman, Yael, Overman, Michael J, Javle, Milind M, Shroff, Rachna T, Varadhachary, Gauri R, Wolff, Robert A, McAllister, Florencia, Futreal, Andrew, Fogelman, David R

“…Family history of -related tumors may correlate with response to chemotherapy and overall survival (OS) in pancreatic cancer. The frequency of germline…”
Get full text

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues by Wolin, Edward M, Jarzab, Barbara, Eriksson, Barbro, Walter, Thomas, Toumpanakis, Christos, Morse, Michael A, Tomassetti, Paola, Weber, Matthias M, Fogelman, David R, Ramage, John, Poon, Donald, Gadbaw, Brian, Li, Jiang, Pasieka, Janice L, Mahamat, Abakar, Swahn, Fredrik, Newell-Price, John, Mansoor, Wasat, Öberg, Kjell

“…In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide long-acting repeatable…”
Get full text

Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer by Schalck, Aislyn, Sakellariou-Thompson, Donastas, Forget, Marie-Andrée, Sei, Emi, Hughes, Tara G, Reuben, Alexandre, Bai, Shanshan, Hu, Min, Kumar, Tapsi, Hurd, Mark W, Katz, Matthew H G, Tzeng, Ching-Wei D, Pant, Shubham, Javle, Milind, Fogelman, David R, Maitra, Anirban, Haymaker, Cara L, Kim, Michael P, Navin, Nicholas E, Bernatchez, Chantale

“…Pancreatic ductal adenocarcinoma (PDAC) has few effective treatments. Immunotherapy, an attractive alternative strategy, remains challenging with the lack of…”
Get more information

Medical oncology and pancreatic cancer: what the radiologist needs to know by Fogelman, David R., Varadhachary, Gauri

“…The majority of PCs present as advanced disease, and treatment goals are for prolongation of life and palliation of the symptoms. Oncologists rely on our…”
Get full text

Association between lower limb spasticity and cryptorchidism in males with cerebral palsy by Bortnick, Eric M., Logvinenko, Tanya, Wang, Hsin‐Hsiao Scott, Fogelman, David J., Shore, Benjamin J., Nelson, Caleb P., Kurtz, Michael P.

“…Aim To explore the association between presence and severity of lower limb spasticity (LLS) and risk of orchidopexy for cryptorchidism among people with…”
Get full text

Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma by Perri, Giampaolo, Prakash, Laura, Qiao, Wei, Varadhachary, Gauri R., Wolff, Robert, Fogelman, David, Overman, Michael, Pant, Shubham, Javle, Milind, Koay, Eugene J., Herman, Joseph, Kim, Michael, Ikoma, Naruhiko, Tzeng, Ching-Wei, Lee, Jeffrey E., Katz, Matthew H. G.

“…OBJECTIVE:We sought to determine whether postoperative chemotherapy after preoperative therapy and pancreatectomy for pancreatic ductal adenocarcinoma (PDAC)…”
Get full text

Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases by BLAZER, Dan G, KISHI, Yoji, ZORZI, Daria, RIBERO, Dario, ELLIS, Lee M, GLOVER, Katrina Y, WOLFF, Robert A, CURLEY, Steven A, ABDALLA, Eddie K, VAUTHEY, Jean-Nicolas, MARU, Dipen M, KOPETZ, Scott, YUN SHIN CHUN, OVERMAN, Michael J, FOGELMAN, David, ENG, Cathy, CHANG, David Z, HUAMIN WANG

“…The primary goal of this study was to evaluate whether pathologic response to chemotherapy predicts patient survival after preoperative chemotherapy and…”
Get full text

Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience by Cloyd, Jordan M., Katz, Matthew H. G., Prakash, Laura, Varadhachary, Gauri R., Wolff, Robert A., Shroff, Rachna T., Javle, Milind, Fogelman, David, Overman, Michael, Crane, Christopher H., Koay, Eugene J., Das, Prajnan, Krishnan, Sunil, Minsky, Bruce D., Lee, Jeffrey H., Bhutani, Manoop S., Weston, Brian, Ross, William, Bhosale, Priya, Tamm, Eric P., Wang, Huamin, Maitra, Anirban, Kim, Michael P., Aloia, Thomas A., Vauthey, Jean-Nicholas, Fleming, Jason B., Abbruzzese, James L., Pisters, Peter W. T., Evans, Douglas B., Lee, Jeffrey E.

“…Background The purpose of this study was to evaluate a single-institution experience with delivery of preoperative therapy to patients with pancreatic ductal…”
Get full text

Physical activity and exercise during preoperative pancreatic cancer treatment by Parker, Nathan H., Ngo-Huang, An, Lee, Rebecca E., O’Connor, Daniel P., Basen-Engquist, Karen M., Petzel, Maria Q.B., Wang, Xuemei, Xiao, Lianchun, Fogelman, David R., Schadler, Keri L., Simpson, Richard J., Fleming, Jason B., Lee, Jeffrey E., Varadhachary, Gauri R., Sahai, Sunil K., Katz, Matthew H.G.

“…Purpose Guidelines recommend exercise to cancer survivors, but limited data exists regarding exercise among patients undergoing preoperative cancer treatment…”
Get full text

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies by Javle, Milind M, Shroff, Rachna T, Xiong, Henry, Varadhachary, Gauri A, Fogelman, David, Reddy, Shrikanth A, Davis, Darren, Zhang, Yujian, Wolff, Robert A, Abbruzzese, James L

“…The phosphoinositide 3-kinase (PI3K)/Akt pathway is constitutively activated in pancreatic cancer and the mammalian target of rapamycin (mTOR) kinase is an…”
Get full text

FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma by Korphaisarn, Krittiya, Morris, Van Karlyle, Overman, Michael J, Fogelman, David R, Kee, Bryan K, Raghav, Kanwal Pratap Singh, Manuel, Shanequa, Shureiqi, Imad, Wolff, Robert A, Eng, Cathy, Menter, David, Hamilton, Stanley R, Kopetz, Scott, Dasari, Arvind

“…FBXW7 functions as a ubiquitin ligase tagging multiple dominant oncogenic proteins and commonly mutates in colorectal cancer. Data suggest missense mutations…”
Get full text

Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients by Mohindroo, Chirayu, Hasanov, Merve, Rogers, Jane E., Dong, Wenli, Prakash, Laura R., Baydogan, Seyda, Mizrahi, Jonathan D., Overman, Michael J., Varadhachary, Gauri R., Wolff, Robert A., Javle, Milind M., Fogelman, David R., Lotze, Michael T., Kim, Michael P., Katz, Matthew H.G., Pant, Shubham, Tzeng, Ching‐Wei D., McAllister, Florencia

“…Recent studies defined a potentially important role of the microbiome in modulating pancreatic ductal adenocarcinoma (PDAC) and responses to therapies. We…”
Get full text

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer by Fogelman, David R, Wolff, Robert A, Kopetz, Scott, Javle, Milind, Bradley, Charles, Mok, Isabel, Cabanillas, Fernando, Abbruzzese, James L

“…Pancreatic cancer is an aggressive, frequently fatal malignancy that strikes 37,000 patients annually in the U.S.A. It is poorly responsive to standard…”
Get full text

Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer by Wang, Ying-Nai, Lee, Heng-Huan, Chou, Chao-Kai, Yang, Wen-Hao, Wei, Yongkun, Chen, Chun-Te, Yao, Jun, Hsu, Jennifer L., Zhu, Cihui, Ying, Haoqiang, Ye, Yuanqing, Wang, Wei-Jan, Lim, Seung-Oe, Xia, Weiya, Ko, How-Wen, Liu, Xiuping, Liu, Chang-Gong, Wu, Xifeng, Wang, Huamin, Li, Donghui, Prakash, Laura R., Katz, Matthew H., Kang, Yaan, Kim, Michael, Fleming, Jason B., Fogelman, David, Javle, Milind, Maitra, Anirban, Hung, Mien-Chie

“…Pancreatic ribonuclease (RNase) is a secreted enzyme critical for host defense. We discover an intrinsic RNase function, serving as a ligand for epidermal…”
Get full text